Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Famciclovir for Active Recurrent Genital Herpes
NCT00171990Phase 3Completed
- Sponsor
- Novartis
- Start
- Jan 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of famciclovir in genital herpes (2 arms), sponsored by Novartis. Primary endpoint: Estimated probability being not lesion-free (i.e. not healed) at 5.5 days. Started Jan 2003; status: completed.
02
Drugs
famciclovir
03
Conditions
genital herpes
Beyond the preview
Go deeper on NCT00171990.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00171990.